Sarcopenia and frailty as predictors of surgical morbidity and oncologic outcomes in retroperitoneal sarcoma

Background Retroperitoneal sarcomas (RPS) are rare tumors for which surgical resection is the principal treatment. There is no established model to predict perioperative risks for RPS. We evaluated the association between preoperative sarcopenia, frailty, and hypoalbuminemia with surgical and oncolo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of surgical oncology 2023-04, Vol.127 (5), p.855-861
Hauptverfasser: Nasirishargh, Aida, Grova, Monica, Bateni, Cyrus P., Judge, Sean J., Nuno, Miriam A., Basmaci, Ugur Nur, Canter, Robert J., Bateni, Sarah B.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Retroperitoneal sarcomas (RPS) are rare tumors for which surgical resection is the principal treatment. There is no established model to predict perioperative risks for RPS. We evaluated the association between preoperative sarcopenia, frailty, and hypoalbuminemia with surgical and oncological outcomes. Methods We performed a prospective cohort analysis of 65 RPS patients who underwent surgical resection. Sarcopenia was defined as Total Psoas Area Index ≤ 1st quintile by sex. Frailty was estimated using the modified frailty index (mFI). Logistic regression models were used to assess predictors of 30‐day postoperative morbidity. The Kaplan–Meier method with log‐rank test was utilized to assess factors associated with overall (OS) and recurrence‐free survival (RFS). Result Sarcopenia was associated with worse OS with a median of 54 compared with 158 months (p = 0.04), but no differences in RFS (p > 0.05). Hypoalbuminemia was associated with worse OS with a median of 72 compared with 158 months (p  0.05). Sarcopenia, mFI, and hypoalbuminemia were not associated with postoperative morbidity (p > 0.05). Conclusion This study suggests that sarcopenia may be utilized as a measure of overall fitness, rather than a cancer‐specific risk, and the mFI is a poor predictive measure of outcomes in RPS.
ISSN:0022-4790
1096-9098
DOI:10.1002/jso.27199